Maria Cuesta-Torres
Family Medicine · Miami, FLNPI 1356598858
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 3 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. Johnson & Johnson accounts for 77.8% of it on its own, with 2 other manufacturers making up the rest. Reporting peaked in 2019 at $92 and has fallen 84.1% since, to $15 in 2023. That places this record below the midpoint for family medicine clinicians in FL, where the typical reported total is $424.
Across 3 payments — averaging $39.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$92
- Novartis$15
- GSK$12
Across 205 payments — averaging $4288.82 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$502K
- Gilead$288K
- Eli Lilly$45K
- Novo Nordisk AS$24K
- Pfizer$20K
What the payments were for
- Food & beverage$118100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 1 | $92 |
| Novartis | 1 | $15 |
| GSK | 1 | $12 |
How this compares
$118 in reported general payments places this provider in the 20th percentile of 7,282 family medicine providers in Florida.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 44 | $46,554 |
| JanuviaSitagliptin Phosphate | 22 | $28,368 |
| EntrestoSacubitril/Valsartan | 20 | $22,710 |
| XareltoRivaroxaban | 12 | $20,050 |
| OzempicSemaglutide | 12 | $17,087 |
| FarxigaDapagliflozin Propanediol | 18 | $11,083 |
| TradjentaLinagliptin | 13 | $9,567 |
| Levothyroxine Sodium | 263 | $3,109 |
| SynthroidLevothyroxine Sodium | 19 | $2,449 |
| Atorvastatin Calcium | 312 | $2,398 |
| Losartan Potassium | 231 | $1,989 |
| Rosuvastatin Calcium | 216 | $1,963 |
| Metoprolol Succinate | 111 | $1,477 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 11 | $1,216 |
| Losartan-HydrochlorothiazideLosartan/Hydrochlorothiazide | 75 | $962 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| NovartisEntresto | $15 | $22,71020 claims |
| Johnson & JohnsonXarelto | $92 | $20,05012 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 20th percentile of 7,282 family medicine providers in Florida.
Other family medicine in Miami
- Clifford KinderMiami$75K
- Robert GoubeauxMiami$67K
- Vanessa RojasMiami$50K
- Michelle PowellMiami$34K
- Ana EloseguiMiami$32K
- Noah LeeOakland Park$1.2M
- Angela RosselotBelle Isle$977K
- Richard LappOrlando$702K
- Hal BrownVero Beach$477K
- Lisa EvansBoca Raton$473K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.